WO1998006749B1 - Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor - Google Patents
Soluble monovalent and multivalent mhc class ii fusion proteins, and uses thereforInfo
- Publication number
- WO1998006749B1 WO1998006749B1 PCT/US1997/014503 US9714503W WO9806749B1 WO 1998006749 B1 WO1998006749 B1 WO 1998006749B1 US 9714503 W US9714503 W US 9714503W WO 9806749 B1 WO9806749 B1 WO 9806749B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- class
- mhc class
- major histocompatibility
- fusion protein
- histocompatibility complex
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims 9
- 102000037865 fusion proteins Human genes 0.000 title claims 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims abstract 9
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000043131 MHC class II family Human genes 0.000 claims 5
- 108091054438 MHC class II family Proteins 0.000 claims 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims 1
- 101000924311 Homo sapiens Desmoglein-3 Proteins 0.000 claims 1
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 102000047598 human DSG3 Human genes 0.000 claims 1
- 102000054064 human MBP Human genes 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Abstract
The present invention is directed to the field of immunology. In particular, the present invention is directed to the design, production, and use of recombinant fusion proteins derived, in part, from the proteins of the human Major Histocompatibility Complex.
Claims
[received by the International Bureau on 20 April 1998 (20.04.98); original claims 26 and 27 amended; remaining claims unchanged (1 page)] 22. A Class II Major Histocompatibility Complex fusion protein as in any one of claims 1-14 further comprising A flexible molecular linker interposed between and covalently joining said MHC Class II chain and said dimerization domain. 23. A Class II Major Histocompatibility Complex fusion protein as in claim 22 wherein said flexible molecular linker comprises a peptide sequence of 1-15 amino acid residues. 24. A Class II Major Histocompatibility Complex fusion protein as in claim 23 wherein said flexible molecular linker comprises a peptide sequence of 5-7 amino acid residues. 25. A Class II Major Histocompatibility Complex fusion protein as in claim 23 wherein a majority of said amino acid residues are selected from the group consisting of alanine, glycine, serine, leucine, isoleucine, and valine residues. 26. A Class II Major Histocompatibility Complex fusion protein as in any one of claims 8-14 further comprising an MHC Class II binding peptide covalently joined to the N-terminus of said MHC Class π β chain, wherein said binding peptide is capable of selectively binding to an MHC Class II molecule including said β chain and an MHC Class II α chain to form an MHC/peptide complex. 27. A Class II Major Histocompatibility Complex fusion protein as in any one of claims 1 -7 further comprising an MHC Class II binding peptide covalently joined to the N-terminus of said MHC Class H a chain, wherein said binding peptide is capable of selectively binding to an MHC Class II molecule including said α chain and an MHC Class II β chain to form an MHC/peptide complex. 28. A Class II Major Histocompatibility Complex fusion protein as in claim 26 wherein said MHC Class II molecule is an HLA-DR2 molecule and said binding peptide is selected from the group consisting of residues 85-99, 84-102 and 148-162 of human myelin basic protein. 29. A Class II Major Histocompatibility Complex fusion protein as in claim 26 wherein said MHC Class II molecule is an HLA-DR4 molecule and said binding peptide is selected from the group consisting of residues 78-93, 97-111, 190-204, 206-220, 251-265, 512-526 and 762-786 of the human desmoglein 3 protein.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU40723/97A AU730457B2 (en) | 1996-08-16 | 1997-08-15 | Soluble monovalent and multivalent MHC class II fusion proteins, and uses therefor |
| AT97938386T ATE272070T1 (en) | 1996-08-16 | 1997-08-15 | SOLUBLE MONOVALENT AND MULTIVALENT MHC CLASS II FUSION PROTEINS AND USES THEREOF |
| DE69730038T DE69730038T2 (en) | 1996-08-16 | 1997-08-15 | SOLUBLE MONOVALENTS AND MULTIVALENTS MHC CLASS II FUSION PROTEINS AND THEIR USE |
| EP97938386A EP0935607B1 (en) | 1996-08-16 | 1997-08-15 | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
| CA002263195A CA2263195A1 (en) | 1996-08-16 | 1997-08-15 | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
| NZ333915A NZ333915A (en) | 1996-08-16 | 1997-08-15 | Soluble monovalent and multivalent MHC class II fusion proteins |
| JP10510100A JP2000516470A (en) | 1996-08-16 | 1997-08-15 | Soluble monovalent and multivalent MHC class II fusion proteins and uses thereof |
| US10/895,543 US20050003431A1 (en) | 1996-08-16 | 2004-07-21 | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2407796P | 1996-08-16 | 1996-08-16 | |
| US60/024,077 | 1996-08-16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/895,543 Continuation-In-Part US20050003431A1 (en) | 1996-08-16 | 2004-07-21 | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998006749A2 WO1998006749A2 (en) | 1998-02-19 |
| WO1998006749A3 WO1998006749A3 (en) | 1998-06-11 |
| WO1998006749B1 true WO1998006749B1 (en) | 1998-07-16 |
Family
ID=21818743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/014503 WO1998006749A2 (en) | 1996-08-16 | 1997-08-15 | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0935607B1 (en) |
| JP (1) | JP2000516470A (en) |
| AT (1) | ATE272070T1 (en) |
| AU (1) | AU730457B2 (en) |
| CA (1) | CA2263195A1 (en) |
| DE (1) | DE69730038T2 (en) |
| DK (1) | DK0935607T3 (en) |
| ES (1) | ES2221065T3 (en) |
| NZ (1) | NZ333915A (en) |
| PT (1) | PT935607E (en) |
| WO (1) | WO1998006749A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9404916B2 (en) | 2008-09-20 | 2016-08-02 | University College Cardiff Consultants Limited | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
| AU729406B2 (en) | 1996-03-28 | 2001-02-01 | Johns Hopkins University, The | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| JP2002504342A (en) * | 1998-02-19 | 2002-02-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Monovalent MHC binding domain fusion proteins and conjugates, multivalent MHC binding domain fusion proteins and conjugates, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| FR2778669B1 (en) * | 1998-05-14 | 2002-06-14 | Centre Nat Rech Scient | PROCESS FOR EXPRESSING A COMPLEX FORMED OF AT LEAST ONE PRODUCT OF THE MAJOR HISTOCOMPATIBILITY COMPLEX AND A PEPTIDE IN A PHAGE, PHAGES AND COMPLEXES OBTAINED THEREFROM AND THEIR APPLICATIONS |
| CA2327314A1 (en) * | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| FR2796953B1 (en) * | 1999-07-29 | 2003-10-10 | Centre Nat Rech Scient | RECOMBINANT PROTEINS, AND MOLECULAR COMPLEXES DERIVED FROM SUCH PROTEINS, ANALOGS TO MOLECULES INVOLVED IN IMMUNE RESPONSES |
| US7521202B2 (en) | 1999-12-17 | 2009-04-21 | The Board Of Regents Of The University Of Oklahoma | Method and apparatus for the production of soluble MHC antigens and uses thereof |
| IL155307A0 (en) | 2000-10-10 | 2003-11-23 | Univ Oklahoma | Methods for isolating, identifying and purifying peptide ligands and peptide ligands produced thereby |
| US20070026433A1 (en) | 2001-03-09 | 2007-02-01 | Hildebrand William H | Epitope testing using soluble HLA |
| IL156473A0 (en) * | 2000-12-18 | 2004-01-04 | Univ Oklahoma | Method and apparatus for the production of antigens |
| WO2002080963A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| ES2559763T3 (en) * | 2002-09-10 | 2016-02-15 | Affimed Gmbh | CD3 specific human antibody with immunosuppressive properties |
| DE602004030451D1 (en) | 2003-07-15 | 2011-01-20 | Chugai Pharmaceutical Co Ltd | PRODUCTION OF IGM BY TRANSFORMED CELLS AND METHOD FOR QUANTIFYING THIS IGM PRODUCTION |
| JP4762717B2 (en) | 2003-10-09 | 2011-08-31 | 中外製薬株式会社 | IgM high concentration stabilization solution |
| GB2409456B (en) * | 2003-10-30 | 2006-01-04 | Proimmune Ltd | Oligomeric receptor ligand pair member complexes |
| EP2155782A2 (en) | 2007-03-26 | 2010-02-24 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| EP2197908A2 (en) | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| GB201002730D0 (en) | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| EP2800582A1 (en) * | 2012-01-06 | 2014-11-12 | Oregon Health & Science University | Partial mhc constructs and methods of use |
| WO2013124474A2 (en) | 2012-02-23 | 2013-08-29 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| US10316075B2 (en) | 2013-10-03 | 2019-06-11 | Oregon Health & Science University | Recombinant polypeptides comprising MHC class II α1 domains |
| JP2017500285A (en) | 2013-11-04 | 2017-01-05 | ユーティーアイ リミテッド パートナーシップ | Methods and compositions for sustained immunotherapy |
| WO2015148960A1 (en) | 2014-03-28 | 2015-10-01 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof |
| RU2020111366A (en) | 2014-05-29 | 2020-04-20 | Мэкроудженикс, Инк. | TRANSPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND ANTIGENS OF MANY MALIGNANT TUMORS, AND WAYS OF THEIR APPLICATION |
| WO2015188839A2 (en) | 2014-06-13 | 2015-12-17 | Immudex Aps | General detection and isolation of specific cells by binding of labeled molecules |
| SG10201913957PA (en) | 2015-05-06 | 2020-03-30 | Uti Lp | Nanoparticle compositions for sustained therapy |
| JP7320944B2 (en) | 2015-10-08 | 2023-08-04 | マクロジェニクス，インコーポレーテッド | Molecules that specifically bind to B7-H3 and molecules that specifically bind to PD-1 |
| CN116875635A (en) | 2015-10-22 | 2023-10-13 | 朱诺治疗学有限公司 | Method, reagent cartridge, reagent and device for transduction |
| MA45489A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS |
| BR112019009477A2 (en) * | 2016-11-09 | 2019-07-30 | Uti Lp | recombinant pmhc class ii molecules |
| IL270142B2 (en) | 2017-04-27 | 2025-05-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| US20220275043A1 (en) * | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| EP3898666A2 (en) | 2018-12-17 | 2021-10-27 | Immudex ApS | Panel comprising borrelia mhc multimers |
| GB201909509D0 (en) * | 2019-07-02 | 2019-08-14 | Immunocore Ltd | Peptide-MHC complexes |
| CN112816595A (en) * | 2021-01-06 | 2021-05-18 | 海默斯（重庆）医学生物技术有限公司 | Recombinant keratin liquid preparation and purity detection method thereof |
| EP4319813A4 (en) * | 2021-04-07 | 2025-03-19 | Repertoire Immune Medicines Inc | PEPTIDE-MHC IMMUNOGLOBULIN MULTIMERS AND METHODS OF USE THEREOF |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3220593A (en) * | 1991-11-19 | 1993-06-15 | Anergen, Inc. | Soluble mhc molecules and their uses |
| AU696177B2 (en) * | 1994-07-29 | 1998-09-03 | Sunol Molecular Corporation | Mhc complexes and uses thereof |
-
1997
- 1997-08-15 WO PCT/US1997/014503 patent/WO1998006749A2/en active IP Right Grant
- 1997-08-15 JP JP10510100A patent/JP2000516470A/en active Pending
- 1997-08-15 NZ NZ333915A patent/NZ333915A/en unknown
- 1997-08-15 DE DE69730038T patent/DE69730038T2/en not_active Expired - Fee Related
- 1997-08-15 AU AU40723/97A patent/AU730457B2/en not_active Ceased
- 1997-08-15 AT AT97938386T patent/ATE272070T1/en not_active IP Right Cessation
- 1997-08-15 DK DK97938386T patent/DK0935607T3/en active
- 1997-08-15 EP EP97938386A patent/EP0935607B1/en not_active Expired - Lifetime
- 1997-08-15 PT PT97938386T patent/PT935607E/en unknown
- 1997-08-15 CA CA002263195A patent/CA2263195A1/en not_active Abandoned
- 1997-08-15 ES ES97938386T patent/ES2221065T3/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9404916B2 (en) | 2008-09-20 | 2016-08-02 | University College Cardiff Consultants Limited | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998006749B1 (en) | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor | |
| Schumacher et al. | Peptide selection by MHC class I molecules | |
| Hackeng et al. | Total chemical synthesis of human matrix Gla protein | |
| EP2298331A3 (en) | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins | |
| AU9174398A (en) | Peptides | |
| Bailey et al. | Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules | |
| CA2265900A1 (en) | Improved solid-phase peptide synthesis and agent for use in such synthesis | |
| CA2148383A1 (en) | Peptide inhibitors of fibronectin and related collagen-binding proteins | |
| WO2006101782A3 (en) | A cysteine-containing peptide tag for site-specific conjugation of proteins | |
| EP0873754A4 (en) | AMINO ACID COMPOSITIONS | |
| WO2001027136A3 (en) | Peptides which stimulate the immune response and tissue regeneration | |
| Tirindelli et al. | Complete amino acid sequence of pyrazine‐binding protein from cow nasal mucosa | |
| TAKAGI et al. | Amino acid sequence of troponin C obtained from ascidian (Halocynthia roretzi) body wall muscle | |
| IE800053L (en) | Muraminyl polypeptides | |
| ATE474589T1 (en) | ANGIOGENIC PEPTIDES AND THEIR USES | |
| Araki et al. | The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure | |
| Futaki et al. | Embodying a stable α-helical protein structure through efficient chemical ligation via thioether formation | |
| WO1994026903A3 (en) | Human influenza virus peptides binding hla-i molecule | |
| GB9917725D0 (en) | Peptides | |
| SI2952521T1 (en) | Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides | |
| EP0794255A3 (en) | Method for cleaving chimeric protein using processing enzyme | |
| AU2957099A (en) | Novel physiologically active peptides and utilization thereof | |
| WO1999002708A8 (en) | Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein | |
| NZ335136A (en) | Isolated peptides which complex with hla-cw*16 molecules, and uses thereof | |
| AU1444699A (en) | Single-chain polypeptides comprising troponin i and troponin |